Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Vertex Pharmaceuticals Incorporated's quarterly P/E stands at 23.3x, down 19.6% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 21.8% YoY to 19.7x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 32.43 | 23.31 | 27.89 | 48.68 | 28.76 | 29.00 | — | 24.82 | 27.42 | 21.90 | 24.99 | 29.28 | 22.92 |
| — | -19.6% | — | +96.1% | +4.9% | +32.4% | — | -15.2% | +19.6% | +8.6% | +11.0% | +32.8% | +25.2% | |
| P/S Ratio | 10.52 | 8.20 | 9.72 | 11.35 | 9.01 | 10.95 | 11.43 | 10.15 | 10.54 | 9.12 | 9.19 | 8.63 | 8.16 |
| — | -25.1% | -15.0% | +11.8% | -14.6% | +20.0% | +24.4% | +17.6% | +29.2% | +13.4% | +10.7% | +7.6% | +19.9% | |
| P/B Ratio | 6.87 | 5.83 | 6.71 | 7.63 | 6.39 | 7.77 | 8.19 | 5.88 | 6.04 | 5.49 | 5.92 | 5.68 | 5.40 |
| — | -25.0% | -18.0% | +29.6% | +5.9% | +41.5% | +38.2% | +3.6% | +11.8% | -4.8% | -3.0% | -7.9% | -3.3% | |
| P/FCF | 39.51 | 22.13 | 31.07 | 40.42 | 53.30 | 23.31 | — | 25.78 | 150.36 | 18.45 | 21.31 | 23.90 | 17.99 |
| — | -5.0% | — | +56.7% | -64.5% | +26.3% | — | +7.9% | +736.0% | -11.5% | +27.1% | +26.8% | +19.0% | |
| EV / EBITDA | 26.63 | 19.71 | 23.24 | 45.24 | 23.80 | 25.19 | — | 21.10 | 23.05 | 18.57 | 19.26 | 22.47 | 15.29 |
| — | -21.8% | — | +114.4% | +3.2% | +35.6% | — | -6.1% | +50.8% | +29.4% | +35.4% | +59.8% | +10.2% | |
| EV / EBIT | 26.63 | 18.77 | 21.73 | 41.85 | 22.40 | 23.92 | — | 19.52 | 20.85 | 16.86 | 17.54 | 20.35 | 15.06 |
| — | -21.5% | — | +114.4% | +7.4% | +41.9% | — | -4.1% | +38.5% | +20.2% | +12.0% | +30.3% | +5.5% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Vertex Pharmaceuticals Incorporated's operating margin was 38.6% in Q3 2025, down 0.3 pp QoQ and down 1.7 pp YoY. The trailing four-quarter average of 33.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 86.5% | 86.3% | 86.9% | 85.5% | 85.8% | 85.9% | 87.3% | 85.4% | 87.2% | 87.6% | 88.8% | 87.7% |
| — | +0.8% | +0.4% | -0.4% | +0.1% | -1.5% | -1.9% | -1.7% | -2.6% | -0.5% | -0.5% | +0.5% | -0.4% | |
| Operating Margin | 39.1% | 38.6% | 38.8% | 22.7% | 35.2% | 40.3% | -132.9% | 42.4% | 39.3% | 41.8% | 41.2% | 32.8% | 44.9% |
| — | -4.3% | +129.2% | -46.4% | -10.3% | -3.7% | -422.7% | +29.3% | -12.5% | -13.4% | -18.3% | -33.9% | +6.0% | |
| Net Margin | 32.9% | 35.2% | 34.8% | 23.3% | 31.4% | 37.7% | -135.8% | 40.9% | 38.5% | 41.7% | 36.7% | 29.5% | 35.6% |
| — | -6.7% | +125.6% | -43.0% | -18.5% | -9.5% | -469.8% | +38.9% | +8.2% | +4.6% | -0.5% | -18.9% | -4.3% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.5% | 6.3% | 6.1% | 3.9% | 5.7% | 6.9% | -21.6% | 6.1% | 5.7% | 6.5% | 6.1% | 4.9% | 6.1% |
| — | -8.7% | +128.4% | -35.5% | +0.3% | +6.2% | -452.2% | +23.3% | -6.5% | -13.2% | -13.7% | -31.9% | -22.5% | |
| ROA | 16.4% | 4.4% | 4.4% | 2.8% | 4.1% | 4.9% | -16.3% | 4.7% | 4.4% | 4.9% | 4.7% | 3.8% | 4.7% |
| — | -10.2% | +127.0% | -39.6% | -6.4% | +0.3% | -450.3% | +25.1% | -7.2% | -14.6% | -14.3% | -31.5% | -20.5% | |
| ROIC | 22.8% | 6.4% | 6.3% | 3.5% | 6.0% | 7.2% | -24.8% | 9.4% | 10.5% | 12.7% | 12.8% | 11.4% | 17.2% |
| — | -11.7% | +125.6% | -63.0% | -42.7% | -43.4% | -293.8% | -17.4% | -39.3% | -34.0% | -36.3% | -38.2% | +10.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Vertex Pharmaceuticals Incorporated's Debt/EBITDA ratio is 1.5x, up from 1.3x last quarter — comfortably within a safe range.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.11 | 0.09 | 0.10 | 0.11 | 0.11 | 0.06 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 |
| — | -2.8% | +40.8% | +157.0% | +131.9% | +141.6% | +27.3% | -28.9% | -28.9% | -28.7% | -30.1% | -31.6% | -32.5% | |
| Debt / EBITDA | 0.79 | 1.48 | 1.27 | 2.43 | 1.63 | 1.46 | — | 0.60 | 0.77 | 0.69 | 0.72 | 0.97 | 0.84 |
| — | +1.6% | — | +302.0% | +111.4% | +111.2% | — | -37.3% | -8.1% | -2.7% | -3.0% | +19.1% | -20.9% | |
| Current Ratio | 2.90 | 2.36 | 2.52 | 2.65 | 2.69 | 2.47 | 2.52 | 3.50 | 3.99 | 4.08 | 4.14 | 4.28 | 4.83 |
| — | -4.3% | -0.0% | -24.4% | -32.5% | -39.6% | -39.1% | -18.3% | -17.4% | -13.2% | -8.0% | -9.8% | +8.1% | |
| Quick Ratio | 2.46 | 2.00 | 2.16 | 2.29 | 2.35 | 2.20 | 2.26 | 3.29 | 3.78 | 3.89 | 3.96 | 4.11 | 4.66 |
| — | -9.0% | -4.7% | -30.4% | -37.7% | -43.6% | -42.8% | -20.0% | -18.9% | -14.5% | -9.1% | -10.6% | +8.4% | |
| Interest Coverage | 352.44 | 359.45 | 311.11 | 210.03 | 366.43 | 148.84 | -355.02 | 109.57 | 93.25 | 95.24 | 91.64 | 68.33 | 89.09 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonVertex Pharmaceuticals Incorporated's current P/E is 32.4x. The average P/E over the last 4 quarters is 32.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vertex Pharmaceuticals Incorporated's current operating margin is 39.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vertex Pharmaceuticals Incorporated's business trajectory between earnings reports.